^
Association details:
| Biomarker: | SLC8A1-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report
Published date:
08/26/2022
Excerpt:
...the patient was diagnosed with "stage IV lung adenocarcinoma"…A rare solute carrier family 8 member A1 (SLC8A1) downstream intergenic region ALK fusion was identified in biopsy specimens using next-generation sequencing (NGS)….The patient received first-line molecular-targeted therapy (ceritinib)....After nearly 9 months, the best evaluation of partial remission (PR) was obtained.
DOI:
10.1097/MD.0000000000030255
